News

World-class endocrine surgeon will be missed by many

Jeffrey Fletcher Moley, MD, professor and chief of the Section of Endocrine and Oncologic Surgery at the Washington University School of Medicine, died on October 15, 2017.  He was an original member of the International Thyroid Oncology Group.  A native of New York City, Jeff received a bachelor's degree from Harvard and an MD degree from the College of Physicians and Surgeons at Columbia University.  He completed his internship and residency at Yale New Haven Hospital, during which he spent three years as a Clinical Associate in the Surgery Branch of the National Cancer Institute.  After a... Continue reading

ITOG Announces Inaugural Robert F. Gagel Discovery Award

Dr. Robert F. Gagel is a principal founder of ITOG. After treating patients with rare thyroid cancers at MD Anderson Cancer Center in Texas, he had the foresight to design a better approach to utilize the limited funding resources available and envisioned a new organization to bring experts together to share research, debate ideas and to develop a logical approach for prioritizing new treatments. In 2004, he and Dr. Barry Nelkin selected a “Dream Team” of physicians and scientists to attend the first ITOG meeting in Bethesda, MD. He worked tirelessly to get the organization off the ground... Continue reading

ITOG Elects New Leadership

The Board of Directors has elected Dr. Manisha Shah as the incoming chair of ITOG.  Her three-year term as the Director of ITOG will begin following the 2018 Annual Meeting in Los Angeles.  Dr. Shah currently serves as ITOG Secretary, Co-chair of the Protocol Committee and has been on the Executive Committee for three years. Dr. Shah is the co-Director of the Neuroendocrine Tumor Program and Professor of Internal Medicine in the Division of Medical Oncology at The Ohio State University, Comprehensive Cancer Center. Dr. Shah's research focuses on the discovery of new targeted therapies for... Continue reading

World Congress on Thyroid Cancer

The 3rd World Congress on Thyroid Cancer took place July 27-30 in Boston, MA. This scientific meeting attracted experts from around the world to share research and ideas to further the understanding of the management of thyroid cancer. Additionally, the delegates attending this congress laid the groundwork for collaborations and the direction of future thyroid cancer research.    Several ITOG members delivered lectures during this exciting meeting. Please see the list below for the lecturers and their topics. Check back for short video clips of some of the lectures which will be posted on... Continue reading

Long term trends in thyroid cancer incidence and mortality

Investigators from the National Cancer Institute, Division of Cancer Epidemiology and Genetics (DCEG), and Duke University Medical Center evaluated long-term trends in thyroid cancer incidence and mortality according to histology, stage, and tumor size at diagnosis. Using data from the SEER-9 cancer registries, they identified 77,276 cases of thyroid cancer diagnosed between 1974 and 2013, of whom 2,371 died of thyroid cancer between 1994 and 2013.  They found that overall incidence of thyroid cancer increased more than threefold over the past four decades, by an average of 3.6% per year,... Continue reading

Update on the interNational Anaplastic Thyroid cancer Tissue bank project (iNATT) www.inatt.org

iNATT

The interNational Anaplastic Thyroid Cancer Tissue Bank and Database project (iNATT) was launched in the UK in 2013 and extended internationally in 2014. The project offers patients with this diagnosis a rare opportunity to participate in research.  By collecting tissue and blood samples along with clinical information from across the UK and from international centres we will be able to gather a significant amount of data which will help us make progress with research in to this difficult to treat disease. We hope to learn more about why and how this type of cancer develops so that we can... Continue reading

Update on ITOG Selumetinib Trial

Dr. Alan Ho

The selumetinib clinical trial led by Dr. Alan Ho of Memorial Sloan Kettering Cancer Center in New York, NY is now open. The trial evaluates the effectiveness of selumetinib to enhance uptake of radioactive iodine (RAI) for treatment of advanced thyroid cancer. This is a large, multicenter, investigator-initiated, randomized, placebo controlled Phase II trial of selumetinib in patients with RAI-avid, recurrent or metastatic thyroid cancer of follicular cell origin. Radioiodine is a key therapy for patients with metastatic thyroid cancer of follicular origin, yet many patients have tumors... Continue reading

Initial Findings of ITOG's First Clinical Trial

Dr. Manisha H. Shah

Preliminary results of the first clinical trial initiated by ITOG have been evaluated, marking a major accomplishment for ITOG. The goal of this multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, is to examine whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with cabozantinib. Dr. Shah reported the initial findings this October at the 15th International Thyroid Congress in Lake Buena Vista, Florida. The abstract of her talk was titled: Cabozantinib in Patients with Radioiodine-Refractory... Continue reading

Philanthropy Exceeds $2.5 Million

Support for the ITOG mission continues to grow with generous contributions from even more supportive donors. Most donations have come from patients, and families of patients, with thyroid cancer who believe that the multi-disciplinary team of ITOG physicians are making a significant difference in improving the treatment of the most challenging thyroid cancers. ITOG received its single largest donation of $500,000 in 2014 from an anonymous donor. Many of ITOG’s member physicians and scientists have also donated to support the organization. Future plans for use of these philanthropic funds not... Continue reading

ITOG Scientists Outline Important Research Benchmarks

ITOG is dedicated to improving the survival and quality of life among patients with thyroid cancer. As part of that mission, the Correlative Sciences Committee of the ITOG has thoughtfully developed a position statement regarding the need for robust correlative studies in thyroid cancer clinical trials to further improve the care of patients with this disease. Correlative science is used to reveal relationships between molecular biomarkers, such as changes in genes and proteins, and clinical outcomes. While meaningful advances have been made in treating metastatic and progressive thyroid... Continue reading

Leadership within ITOG Expands

Recognizing Dr. Sherman's leadership

The Board of Directors has elected Dr. Lori Wirth as the new chair of ITOG. She will serve a three-year term. Dr. Wirth previously chaired the Protocol Committee, the group responsible for selecting ITOG clinical trials, and also served as ITOG Secretary. Dr. Wirth is the Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital. Dr. Manisha Shah, an oncologist at Ohio State University, joins the Executive Committee as the newly elected ITOG Secretary. Dr. Shah was previously chair of the Membership Committee and served on the Protocol Committee, all while... Continue reading

A Truly International Annual Meeting

For the first time in ITOG history, the Annual Meeting was held in Europe. ITOG members Dr. Sebastiano Filetti and Dr. Martin Schlumberger hosted an exceptional two-day gathering at Sapienza Università di Roma in Rome, Italy, where Dr. Filetti is a member of the faculty. The inspiring agenda was complete with presentations of groundbreaking research, the latest results from clinical trials, and innovative approaches employed in other cancer diagnoses that could be translated for thyroid cancer research. Dr. Thomas Giordano gave an extremely informative talk on the molecular characterization... Continue reading

Cabozantinib impact on thyroid tumor shrinkage

Dr. Manisha Shah, ITOG investigator, discusses the impact of cabozantinib on thyroid tumor shrinkage.  Watch the video here:  http://bit.ly/1H4Xw6O Click here for the video.  

Clinical trial of a very well tolerated drug for an uncommon form of thyroid cancer

The drug Pioglitazone (Actos) is being used in a clinical trial for thyroid cancers that contain a specific mutation called PAX8-PPARgamma. PAX8-PPARgamma is uncommon, but is found in some thyroid cancers of the following types: follicular; follicular variant of papillary; and poorly differentiated. An exciting aspect of this trial is that pioglitazone has few if any side effects, and in fact it is FDA-approved for the long term therapy of diabetes. The only potentially significant side effects are mild fluid retention and mild weight gain. The drug is specific for PAX8-PPARgamma and is not... Continue reading

Molecular characterization of thyroid cancers reported at ITOG Annual Meeting

Thomas Giordano

The 2015 ITOG International Meeting was recently held in Rome, Italy, where Dr. Thomas Giordano presented the lead talk on a new comprehensive analysis of thyroid cancer from The Cancer Genome Atlas (TCGA) Research Network, a federally funded project to elucidate the molecular characterization of various cancer types. Dr. Giordano’s findings are extremely important to the thyroid cancer community and will potentially change the way thyroid cancers are classified and diagnosed. Further, the identification of new markers of aggressive tumors could allow for better targeting of tailored... Continue reading

Pages

Contact

International Thyroid Oncology Group
5166 Commercial Drive
Yorkville, New York 13495